Roche's breast cancer drug Kadcyla wins first European nod; FDA warns of IQ effects from Depakote in pregnancy;

@FiercePharma: Lilly salesforce cuts to be deeper than expected, Indy Biz Journal says: 1,624 jobs, or 40%, not 30%. Report | Follow @FiercePharma

@EricPFierce: Eli Lilly's CEO John C. Lechleiter will have surgery and be out for some weeks. Release | Follow @EricPFierce

> Roche's ($RHHBY) breast cancer drug Kadcyla won its first approval in Europe as Swiss authorities cleared it for use there. Report

> The FDA warned that pregnant women's use of drugs containing valproate sodium, such as Abbott Laboratories' ($ABT) Depakote, may result in lower IQ scores in their children. Report

> The U.K.'s plans to move to value-based pricing for drugs have drawn fire from a health policy think tank, 2020health, which is partly funded by the pharma industry. Report (sub. req.)

> A drug developer, RedxPharma, has agreed to move into former AstraZeneca ($AZN) labs in Alderley Park, England, creating 120 jobs at the site soon to be downsized by the larger company. Report (sub. req.)

Medical Device News

@FierceMedDev: Hologic slashes outlook as losses widen. Report | Follow @FierceMedDev

@MarkHFierce: Dx test maker Quidel now owns BioHelix, for $10M, plus milestone payments. Item | Follow @MarkHFierce

 @DamianFierce: Medtronic won FDA approval for two new cardiac devices. Story | Follow @DamianFierce

> Mindray soars in Q1 with 21% Dx growth. Report

> Mass General repurposes cancer Dx tool for multiple use. DxExtra

Biotech News

@FierceBiotech: NGM raises $13M for cardio/metabolic R&D work. Item | Follow @FierceBiotech

@JohnCFierce: Astellas, VCs stake virtual biotech spinout with $15M and a PhII program. Release | Follow @JohnCFierce

@RyanMFierce: Pfizer opts to keep running Accelrys software in its labs. Article | Follow @RyanMFierce

> GlaxoSmithKline's "independent experts" start to hand out keys to its data vault. Story

> Baxter adds Gammagard to growing roster of PhIII Alzheimer's failures. Article

> Celgene nabs another round of promising pivotal apremalist data for psoriatic arthritis. Report

Pharma Manufacturing News

> Pfizer sells Viagra online to take away play by counterfeiters. Item

> Novo investing $67M in Denmark plant. Article

> J&J dealing with OTC manufacturing issues on 3 continents. Story

> Sagent buys full control of China plant. News

Biotech Research News

 @EmilyMFierce: New molecule could be potential therapy for muscular dystrophy. More | Follow @EmilyMFierce

> Inhibiting a protein could provide new avenue for antidepressant drug development. Report

> Genetic "switch" could halt aggressive cancer growth. More

> Scientists create more accurate animal model of Type 2 diabetes. Story

> Mayo Clinic develops drug that stops growth of kidney cancer. Article

And Finally... Scientists figured out the way stress hormones interfere with brain-cell birth, laying a possible foundation for new antidepressants. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

A phase 1 study of the Inlyta-Keytruda regimen, which bears a first-line nod for kidney cancer, got the ax along with several Bavencio tests.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.